^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | magrolimab (GS-4721) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
Published date:
09/15/2020
Excerpt:
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome (MDS).
Source:
Title:
Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
Published date:
09/03/2019
Excerpt:
Forty Seven, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to magrolimab (formerly known as 5F9) for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
